The most typical serious adverse occasions include disease progression, pyrexia and cellulitis. Serious adverse events happened in 26 % of talimogene laherparepvec sufferers and 13 % of GM-CSF patients. Trial Design This trial was a worldwide, randomized, open-label, Phase 3 trial to judge the security and efficacy of talimogene laherparepvec in comparison to a control therapy with GM-CSF in over 400 individuals with unresected stage IIIB, IV or IIIC melanoma. Treatment could last for to 18 months up. Where appropriate, stable or responding individuals could receive extra treatment on an extension protocol.. AMGEN announces additional results from talimogene laherparepvec Stage 3 trial AMGEN today announced additional outcomes from a pivotal Phase 3 trial evaluating talimogene laherparepvec in individuals with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor .This innovation represents an alternative solution to the usage of chemical or antibiotics decontamination in food supply systems. Using character as their inspiration, the researchers successfully attached cell lytic enzymes to food-secure silica nanoparticles, and created a coating with the demonstrated ability to selectively eliminate listeria-a harmful foodborne bacteria that causes around 500 deaths every year in the United States. The covering kills listeria on contact, even at high concentrations, within a couple of minutes without affecting other bacteria.